<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04478942</url>
  </required_header>
  <id_info>
    <org_study_id>UPH-Meriter IRB 2020-003</org_study_id>
    <secondary_id>A532860</secondary_id>
    <secondary_id>SMPH/OBSTET &amp; GYNECOL</secondary_id>
    <secondary_id>Protocol Version 1/29/2020</secondary_id>
    <nct_id>NCT04478942</nct_id>
  </id_info>
  <brief_title>PROMMO Trial: Oral Misoprostol vs IV Oxytocin</brief_title>
  <acronym>PROMMO</acronym>
  <official_title>PROMMO Trial: Prelabor Rupture of Membranes Managed With Oral Misoprostol Versus Intravenous Oxytocin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized trial looking at the ideal method of labor induction for&#xD;
      women with prelabor rupture of membranes and an unfavorable cervical Bishop score. The study&#xD;
      will compare oral misoprostol and intravenous oxytocin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to look at optimal induction management of prelabor rupture of&#xD;
      membranes (PROM) at or beyond 34 weeks gestational age.&#xD;
&#xD;
      Objective 1: To determine if there is a decrease in time from initiation of induction of&#xD;
      labor to vaginal delivery in women with an unfavorable cervix with the use of oral&#xD;
      misoprostol versus intravenous oxytocin.&#xD;
&#xD;
      Hypothesis: Cervical ripening with misoprostol will be beneficial in women with an&#xD;
      unfavorable cervix.&#xD;
&#xD;
      Sub objective 1: To determine if the use of oral misoprostol for cervical ripening decreases&#xD;
      the rate of postpartum hemorrhage in women with PROM.&#xD;
&#xD;
      Hypothesis: Misoprostol use will result in significantly lower rate of postpartum hemorrhage.&#xD;
&#xD;
      Sub objective 2: To evaluate the rates of infectious morbidity in peripartum women and&#xD;
      neonates exposed to misoprostol versus oxytocin in PROM.&#xD;
&#xD;
      Hypothesis: The use of oral misoprostol will result in lower rates of infectious morbidity in&#xD;
      mother and neonate.&#xD;
&#xD;
      Sub objective 3: To analyze patient satisfaction surveys. Hypothesis: Patients in the oral&#xD;
      misoprostol group will be more satisfied with their labor experience.&#xD;
&#xD;
      Exploratory Outcome To determine if there is a difference in cost between induction of labor&#xD;
      in women with an unfavorable cervix with the use of oral misoprostol versus intravenous&#xD;
      oxytocin.&#xD;
&#xD;
      Hypothesis: The use of oral misoprostol will be cost effective in women presenting with PROM&#xD;
      and an unfavorable cervix.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint: Time from initial medication administration to vaginal delivery</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>time from initiation of induction of labor to vaginal delivery in women with an unfavorable cervix with the use of oral misoprostol versus intravenous oxytocin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint 1: Rate of Postpartum Hemorrhage</measure>
    <time_frame>up to 24 hours for immediate postpartum hemorrhage</time_frame>
    <description>the rate of postpartum hemorrhage in women with prelabor rupture of membranes with use of oral misoprostol for cervical ripening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint 2: Rate of Suspected or Confirmed Intrapartum Intramniotic Infection</measure>
    <time_frame>Prior to delivery</time_frame>
    <description>Rates of infectious morbidity in peripartum women and neonates exposed to misoprostol versus oxytocin in prelabor rupture of membranes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint 3: Rate of Suspected Endometritis</measure>
    <time_frame>From delivery to 6 weeks postpartum</time_frame>
    <description>patient satisfaction surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint 4: Rate of Infectious Morbidity for Neonates</measure>
    <time_frame>up to 6 weeks of life</time_frame>
    <description>Neonatal infection that is diagnosed within the first 6 weeks of life related to maternal infection diagnosed by positive blood cultures or fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint 5: Participant Satisfaction as Measured by modified Labour Agentry Scale</measure>
    <time_frame>Postpartum day one with repeat instrument at 6 weeks postpartum</time_frame>
    <description>The modified labour agentry scale has scores that indicate satisfaction with the patient's experience in labor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Premature Rupture of Membrane</condition>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>oral misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At time of delivery, participants randomly assigned to either oral misoprostol will receive 50 mcg of Misoprostol every 4 hours up to 6 doses, OR until simplified Bishop score &gt;6 (whichever is achieved first).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At time of delivery, participants randomly assigned to intravenous oxytocin, will be administered the drug per standard of labor and delivery titrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol Oral Product</intervention_name>
    <description>Misoprostol will be dosed using the preexisting UnityPoint Health-Meriter Protocol for oral misoprostol administration.</description>
    <arm_group_label>oral misoprostol</arm_group_label>
    <other_name>Oral Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Oxytocin</intervention_name>
    <description>Intravenous oxytocin administration will also follow standard, UnityPoint Health-Meriter Protocol.</description>
    <arm_group_label>intravenous oxytocin</arm_group_label>
    <other_name>IV Product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Early Term to late term pregnancy (&gt;37 weeks and 0 days and &lt;42 weeks and 0 days)&#xD;
&#xD;
          -  Late Preterm Pregnancy (34 weeks and 0 days and &lt;37 weeks)&#xD;
&#xD;
          -  Confirmed rupture of membranes by either sterile speculum exam or AmniSure&#xD;
&#xD;
          -  Simplified Bishop Score â‰¤ 6&#xD;
&#xD;
          -  Maternal Age &gt; 18 years old&#xD;
&#xD;
          -  Singleton gestation&#xD;
&#xD;
          -  Appropriate gestational age dating by certain LMP or ultrasound performed prior to 20&#xD;
             weeks gestational age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concern for intra-amniotic infection&#xD;
&#xD;
          -  Previous Cesarean delivery&#xD;
&#xD;
          -  Lack of appropriate dating criteria for the pregnancy&#xD;
&#xD;
          -  Inability to give informed consent in the patient's native language&#xD;
&#xD;
          -  Known bleeding disorder such as von Willebrand's disease or hemophilia&#xD;
&#xD;
          -  Anticoagulation administration within 24 hours of delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacquelyn Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon E Blohowiak, MS</last_name>
    <phone>608-417-6957</phone>
    <email>sblohowiak@wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacquelyn Adams, MD</last_name>
    <phone>(608) 417-7427</phone>
    <email>jadams@uwhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UnityPoint Health- Meriter Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-2216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Adams</last_name>
      <phone>608-417-7427</phone>
      <email>jadams@uwhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

